Published in:
Open Access
01-12-2016 | Research
H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets
Authors:
Huan-Di Liu, Ai-Jie Zhang, Jing-Jing Xu, Ying Chen, Yi-Chun Zhu
Published in:
Journal of Hematology & Oncology
|
Issue 1/2016
Login to get access
Abstract
Background
Our previous pilot studies aimed to examine the role of hydrogen sulfide (H2S) in the generation of endothelial progenitor cells led to an unexpected result, i.e., H2S promoted the differentiation of certain hematopoietic stem/progenitor cells in the bone marrow. This gave rise to an idea that H2S might promote hematopoiesis.
Methods
To test this idea, a mice model of myelosuppression and cultured fetal liver cells were used to examine the role of H2S in hematopoiesis.
Results
H2S promoted the generation of megakaryocytes, increased platelet levels, ameliorate entorrhagia, and improved survival. These H2S effects were blocked in both in vivo and in vitro models with thrombopoietin (TPO) receptor knockout mice (c-mpl−/− mice). In contrast, H2S promoted megakaryocytes/platelets generation in both in vivo and in vitro models with TPO knockout mice (TPO−/− mice).
Conclusions
H2S is a novel promoter for megakaryopoiesis by acting on the TPO receptors but not TPO to generate megakaryocytes/platelets.